Latest News

How Marqeta’s Recent Performance Frames Today’s Investment Debate Marqeta (MQ) has seen mixed share performance, with a 2.4% gain over the past day and 8.2% over the past week, set against weaker returns over the past month and past 3 months. For investors, that contrast, alongside annual revenue of about US$588.6 million and a reported net loss of US$39.6 million, keeps the focus on how the company’s card issuing platform and growth in financial metrics might balance ongoing profitability...

Dover (DOV) has attracted fresh attention after recent trading left the stock at $233.31, with returns of 0.3% over the past day and 27.5% over the past 3 months catching investors’ eyes. See our latest analysis for Dover. Beyond the latest move, Dover’s momentum has been building, with a 12.9% 1 month share price return and multi year total shareholder returns above 60%, suggesting investors have been reassessing both growth potential and risks. If Dover’s climb has you thinking about where...

If you are wondering whether ASML Holding's share price still reflects reasonable value, you are not alone. That is exactly what this article will unpack for you. The stock last closed at €1,249.20, with returns of 4.5% over 7 days, 6.0% over 30 days, 26.7% year to date, 76.6% over 1 year, 115.5% over 3 years and 172.2% over 5 years. Recent coverage around ASML has focused on its central role in semiconductor equipment supply chains and the market's expectations for chip industry demand...

If you are wondering whether Whirlpool's current share price is giving you genuine value or just looks cheap at first glance, this article will walk through what the numbers are actually saying. Whirlpool shares most recently closed at US$84.49, with a 7 day return of a 4.7% decline, a 30 day return of a 1.1% decline, a year to date gain of 13.4%, and a 1 year return of a 14.3% decline, set against a 3 year return of a 27.0% decline and a 5 year return of a 43.3% decline. These mixed returns...

AstraZeneca received U.S. FDA approval for CALQUENCE with venetoclax as the first all oral, fixed duration regimen for chronic lymphocytic leukemia and small lymphocytic lymphoma. The FDA granted orphan drug designation to surovatamig for follicular lymphoma. ENHERTU, developed with Daiichi Sankyo, had its marketing application validated by the EMA for HER2 positive breast cancer. For investors watching LSE:AZN, these updates add fresh detail to an already active oncology story. The shares...

For readers wondering whether Keysight Technologies at around US$243 per share still offers value or if the easy money is already gone, this article will walk through what the current price might be implying. The stock has returned 4.3% over the last 7 days, 14.4% over the past month, 17.9% year to date and 38.8% over the past year, with longer term returns of 54.3% over 3 years and 72.1% over 5 years. Recent coverage has focused on Keysight's role in electronic design and test solutions, as...

XPeng (NYSE:XPEV) has launched a unified global in-app charging payment solution through a new partnership with Antom. The rollout begins outside mainland China with coverage in Hong Kong and planned expansion into Southeast Asia. The service enables cross-border, multi-currency payments for electric vehicle charging within XPeng's ecosystem. XPeng, an electric vehicle maker listed on the NYSE under ticker XPEV, is expanding its charging and software ecosystem as global EV adoption scales...

Ford Motor (NYSE:F) has outlined a shift toward affordable electric vehicles and hybrids, anchored by a new Universal EV Platform. The company is pairing this platform with fresh model plans that target cost conscious buyers and respond to tougher global EV competition, including pressure from Chinese automakers. This pivot follows ongoing challenges in Ford's EV efforts and is intended to realign its product mix with changing customer preferences. For investors watching NYSE:F, this news...

Merck (NYSE:MRK) plans to split its Human Health business into two divisions: one for oncology and one for specialty, pharma, and infectious diseases. The restructuring is tied to the anticipated patent loss of cancer drug Keytruda and is intended to sharpen management focus across franchises. New leadership roles, more than 20 identified growth drivers, and a deep Phase 3 pipeline are central elements of the new setup. For you as an investor, the move highlights how central oncology has...

Natera recently attracted positive attention after Duquesne Family Office highlighted the company’s strong oncology testing momentum, including 54% growth in third-quarter oncology volumes and expanding use of its Signatera molecular residual disease blood test, which now represents nearly a quarter of total tests. While Natera remains unprofitable, its recurring revenue base, cash generation and scalable diagnostics platform across women’s health, oncology and organ health are drawing...

If you are wondering whether Doximity is starting to look like value or is still priced for high expectations, you are in the right place to assess what the current share price really reflects. The stock most recently closed at US$25.55, after a 2.1% move over the past week, but with much steeper returns of a 37.1% decline over 30 days, a 41.0% decline year to date, and a 64.7% decline over the past year. These sharp price moves have come alongside ongoing discussion about Doximity's role as...

American Tower (NYSE:AMT) reported recent insider selling by its chief financial officer, involving a substantial stock sale. The company also appointed a new chief accounting officer, marking a change in its senior finance leadership team. These developments highlight fresh corporate governance and oversight moves that investors may wish to watch closely. American Tower operates as a global owner and operator of wireless and broadcast communications infrastructure, a business that sits at...

Loblaw Companies stock: why investors are paying attention Loblaw Companies (TSX:L) has drawn fresh attention after recent trading left the share price at CA$67.26, with returns over the past month and past 3 months outpacing its 7 day move. See our latest analysis for Loblaw Companies. Despite a 1 day share price return of negative 1.92% bringing the stock to CA$67.26, Loblaw Companies still shows stronger recent momentum, with a 30 day share price return of 6.83% and a 1 year total...

If you are wondering whether Scholar Rock Holding's recent share price puts it on sale or already prices in a lot of optimism, you are asking the right question for a valuation focused look at the stock. The shares recently closed at US$48.00, with returns of 4.4% over 7 days, 8.4% over 30 days, 12.1% year to date, 27.3% over 1 year, a very large gain over 3 years, and a 11.3% decline over 5 years. This naturally raises questions about how much upside or risk is now built into the...

BioLife Solutions (BLFS) shares are in focus after the company entered a multi year supply agreement with Qkine Limited. The deal secures exclusive worldwide distribution rights to selected cytokine and growth factor products for cell and gene therapy manufacturing. See our latest analysis for BioLife Solutions. Despite the Qkine agreement, BioLife Solutions’ share price return has been mixed, with a 7 day gain of 3.87% but a 30 day and year to date share price decline. The 1 year total...

Novo Nordisk's next generation obesity drug CagriSema underperformed Eli Lilly's tirzepatide in a major late stage clinical trial. The trial result means CagriSema did not meet its primary goal of matching the effectiveness of the rival therapy. This setback raises fresh questions about Novo Nordisk's future product pipeline and approach to the fast growing obesity care market. For investors watching CPSE:NOVO B, this development comes after a period of weaker share performance. The stock...

Latest results set the stage for the Tourism Holdings narrative Tourism Holdings (NZSE:THL) has reported H1 2026 results with revenue of $478.9 million and a basic EPS loss of $0.23 per share, alongside net income of a $51.0 million loss. The company has seen revenue move from $472.5 million in H2 2024 to $458.4 million in H1 2025 and then to $478.9 million in H2 2025, while EPS has swung from a near breakeven loss of $0.00 to a $0.12 profit and back to a $0.23 loss over those periods. For...

Earlier this week, UBS upgraded BlackRock to Buy after the asset manager reported strong fourth‑quarter results and highlighted a solid start to first‑quarter fund flows at the UBS Financials conference. This shift in analyst stance comes even as BlackRock manages headwinds such as outflows from its Bitcoin ETFs and concerns around private market liquidity, underlining how its broader business mix is shaping perceptions. We’ll now examine how UBS’s more positive view on BlackRock’s earnings...

Taylor Morrison Home recently launched its “Homes Built for Real Life” brand platform, highlighting authentic everyday living, while also reporting full-year 2025 revenue of US$8,121.48 million and net income of US$782.5 million, alongside a larger, extended share repurchase authorization through 2027. The combination of a consumer research-driven brand aimed at millennial and Gen Z buyers and an upsized US$1,000 million buyback plan underscores how Taylor Morrison is aligning its marketing,...

Why EVERTEC Just Caught Investor Attention EVERTEC (EVTC) is back on watch after a recent move in the share price, with the stock up 1.6% on the day and 4.5% over the past week despite weaker year and multi year returns. See our latest analysis for EVERTEC. The recent 1 day share price return of 1.62% and 7 day gain of 4.48% stand in contrast to a 30 day share price return of 7.55% and a 1 year total shareholder return of 16.53%. This points to short term momentum building after a weaker...

Wondering if Lockheed Martin's current share price reflects its true worth, or if the market is getting ahead of itself? This article is going to walk you through what the numbers actually say about value. Lockheed Martin closed at US$658.26 recently, with returns of 0.9% over 7 days, 11.4% over 30 days, 32.4% year to date and 53.8% over the past year. These figures have many investors asking whether the stock's risk and reward are still in balance. Recent headlines have focused on Lockheed...

What recent performance says about Herbalife stock Herbalife (HLF) has drawn fresh attention after a strong run, with the share price at $19.96 and total return figures of 20% over the past month and 67% over the past 3 months. For longer term holders, the stock shows a 56% decline over 5 years, alongside a 140% total return over the past year and a modest 2% total return over 3 years. This highlights mixed holding period experiences. See our latest analysis for Herbalife. The recent surge in...

If you are wondering whether First Majestic Silver's recent share price action still leaves any value on the table, this article walks through what the numbers are really saying about the stock. The share price last closed at C$37.70, with returns of 20.5% over 7 days, 8.3% over 30 days, 70.9% year to date and 368.5% over 1 year, so recent moves have been sizeable. These returns sit against a backdrop where silver focused miners have been closely watched by investors and headlines have been...

If you are wondering whether Hitachi's current share price still reflects good value after a strong multiyear run, you are not alone. The stock most recently closed at ¥4,930, with returns of 19.0% over 1 year, very large gains over 5 years of around 4.5x, but with shorter term pullbacks of 5.4% over 7 days, 7.0% over 30 days and 2.7% year to date. These recent moves have come as investors continue to react to ongoing headlines around Hitachi's broad business mix, including its exposure to...